Evaluation of the efficacy and safety of clindamycin plus pyrimethamine for induction and maintenance therapy of toxoplasmic encephalitis in AIDS

  • C. Katlama
Current Topic: Notes

Abstract

Through the European Network in the Treatment of AIDS, a multicenter trial is being conducted to compare the efficacy and safety of pyrimethamine (50 mg/day) plus clindamycin (2.4 g/day) with the regimen of pyrimethamine (50 mg/day) and sulfadiazine (4.0 g/day) for induction and maintenance treatment of toxoplasmic encephalitis. By 1 September 1990, 281 patients had been randomized to enter the study. Preliminary data show that 77 % of the 148 patients evaluated showed a complete response or improvement with minor sequelae during therapy. Twenty percent of the patients deteriorated. This was due to toxoplasmosis in only 10 % of the patients. Side-effects were common in all patients regardless of treatment regimen and consisted mainly of rash (52 cases), fever (31 cases), diarrhea (17 cases) and nausea (12 cases). The final analysis should be available by the middle of 1991.

Keywords

Internal Medicine Diarrhea Treatment Regimen Encephalitis Final Analysis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Remington JS, Desmonts G Toxoplasmosis. In: Remington JS, Klein JO (ed): Infectious diseases of the fetus and newborn infant. Saunders, Philadelphia, 1990, p. 89–195.Google Scholar
  2. 2.
    Grant IH, Gold JWM, Armstrong D: Risk of CNS toxoplasmosis in patients with acquired immune deficiency syndrome. In: Program and Abstracts of the 26th Interscience Conference of Antimicrobial Agents and Chemotherapy, New Orleans, 1986, Abstract no. 441.Google Scholar
  3. 3.
    Leport C, Raffi F, Matheron S, Katlama C, Regnier B, Saimot AG, Marche C, Vedrenne C, Vildé JL Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with acquired immunodeficiency syndrome: efficacy of long term continuous therapy. American Journal of Medicine 1988, 84: 94–100.PubMedGoogle Scholar
  4. 4.
    Haverkos HW The TE Study Group: Assessment of therapy for toxoplasma encephalitis. American Journal of Medicine 1987, 82: 907–914.PubMedGoogle Scholar
  5. 5.
    Araujo FG, Remington JS Effect of clindamycin on acute and chronic toxoplasmosis in mice. Antimicrobial Agents and Chemotherapy 1974, 5: 647–651.PubMedGoogle Scholar
  6. 6.
    Rolston KVI, Hoy J Role of clindamycin in the treatment of central nervous system toxoplasmosis. American Journal of Medicine 1987, 83: 551–554.PubMedGoogle Scholar
  7. 7.
    Dannemann BR, Israelski DM, Remington JS Treatment of toxoplasmic encephalitis with intravenous clindamycin. Archives of Internal Medicine 1988, 148: 2477–2482.PubMedGoogle Scholar
  8. 8.
    Tedesco FJ Clindamycin and colitis: a review. Journal of Infectious Diseases 1977, 135, Supplement: 95–98.Google Scholar

Copyright information

© Friedr. Vieweg & Sohn Verlagsgesellschaft mbH 1991

Authors and Affiliations

  • C. Katlama
    • 1
  1. 1.Department of Infectious Diseases and Tropical MedicineHôpital Pitié-SalpêtrièreParis Cedex 13France

Personalised recommendations